ANTIHYPERTENSIVE AND ANTIOXIDATIVE EFFECTS OF CARVEDILOL AND METOPROLOL IN HYPERTENSIVE PATIENTS WITH OVERWEIGHT/OBESITY

Aim. To evaluate an efficacy of the 24-week antihypertensive therapy based on the carvedilol or metoprolol and its influence on markers of blood oxidative status in hypertensive patients with overweight/obesity.

Material and methods. The observation data of 20 hypertensive patients (aged 40-65 y.o.) with overweight/obesity were analyzed. Blood pressure (BP) dynamics at each visit and a rate of target BP achievement were evaluated. Blood oxidative status was evaluated by plasma malondialdehyde (MDA) level and erythrocyte superoxide dismutase (SOD) activity. Therapy safety was evaluated by adverse events registration.

Results. Significant reduction in both systolic and diastolic BP compared with baseline values was found. BP targets were achieved in all patients in both groups. The therapy based on carvedilol had a greater effect on blood oxidative status in comparison with metoprolol therapy. Plasma MDA level reduced from 7.03 [6.49;7.41] to 3.23 [2.88;3.57] μM/l (p<0.05) vs from 6.95 [6.51;7.39] to 6.08 [5.46;6.71] μM/l, respectively, and erythrocyte SOD activity increased from 27,89 [25.29;30.49] to 40.18 [35.89;44.45]% (p<0.05) vs from 28.41 [25.18;31.64] to 33.45 [30.65;36.23]%, respectively.

Conclusion. The high antihypertensive efficacy, positive effect on blood oxidative status and well tolerability of therapy based on carvedilol in everyday clinical practice is presented.

1. Шальнова С.А., Баланова Ю.А., Константинов В.В. и др. Артериальная гипертония: распространенность, осведомленность, при- ем антигипертензивных препаратов и эффективность лечения среди населения Российской Федерации. Российский кардиологический журнал 2006;(4):45-50.

2. Марцевич С.Ю., Кутишенко Н.П., Шилова Е.В. и др. от имени рабочей группы по проведению исследования «КАМЕЛИЯ». Карведилол в лечении пациентов с артериальной гипертонией и избыточной массой тела/ожирением. Результаты исследования «КАМЕЛИЯ». Трудный пациент 2009;(4-5):19-23.

3. Wofford M.R., Anderson D.C. Jr., Brown C.A. et al. Antihypertensive effect of alfa-and beta-adrenergic blockade in obese and lean hyperten￾sive subjects. Am J Hypertens 2001;14(7 Pt 1):694-8.

4. Lindholm L.H., Carlberg B., Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366(9496):1545-53.

5. Преображенский Д.В., Сидоренко Б.А., Дедова И.С., Тарыкина Е.В. Блокаторы β-адренорецепторов в лечении сердечно-сосудистых заболеваний: место карведилола. Кардиология 2006;46(12): 32-6.

6. Stienen U. The once-daily dose regimen of carvedilol: a meta-analysis approach. J Cardiovasc Pharmacol 1992;19 Suppl 1:S128-33.

7. Brehm B.R., BertschD., von Fallois J., Wolf S.C. Beta-blockers of the third generation inhibit endothelium-I liberation mRNA production and proliferation of human coronary smooth muscle and endothelial cells. J Cardiovasc Pharmacol 2000; 36(5 Suppl 1):S401-3.

8. Taddei S., Virdis A., Ghiadoni L. et al. Endothelial dysfunction in hypertension. J Cardiovasc Pharmacol 2001;38 Suppl 2:S11-4.

9. Yue T.L., Mckenna P.J., Lysko P.G. et al. SB 211475, a metabolite of carvedilol, a novel antihypertensive agent, is a potent antioxidant. Eur J Pharmacol 1994; 251:237-43.

10. Devereaux P.J., Beattie W.S., Choi P.T. et al. How strong is the evidence for the use of perioperative beta blockers in non-cardiac surgery? Systematic review and meta-analysis of randomised controlled trials. BMJ 2005;331(7512):313-21.

11. Loscalzo J. Oxidative stress in endothelial cell dysfunction and thrombosis. Pathophysiol Haemost Thromb 2002;32(5-6):359-60.

12. Lefer D.J., Granger D.N. Oxidative stress and cardiac disease. Am J Med 2000;109(4):315-23.

13. Марцевич С.Ю., Кутишенко Н.П., Шилова Е.В. и др. от имени рабочей группы по проведению исследования «Камелия». Сравнение терапии, основанной на карведилоле или метопрололе, у больных артериальной гипертонией и избыточной массой тела/ожирением. Первые результаты исследования «Камелия». Рациональная Фармакотерапия в Кардиологии 2009;5(1):23-7.